peptide,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM,netmhcpan_ba_BAV,ann_BAV,smmpmbec_BAV,smm_BAV,mhcflurry_BAV,netmhcpan_ba_BAV_Normalized,ann_BAV_Normalized,smmpmbec_BAV_Normalized,smm_BAV_Normalized,mhcflurry_BAV_Normalized,VRAPERNet_BAV_Normalized,VRAPERNet_BAV
KLVVVGAVGV,Positive,=,35810.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.030850523240273375,174.89,300.18,102.75903093107507,156.12771368448506,52.25,0.5227113653241957,0.472781960518789,0.5718593653197246,0.5331998293294178,0.6343695973377759,0.2881366014480591,2213.2208707843024
LLVVGAAGV,Positive,=,17540.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.09681705030808807,48.88,91.02,81.1764397428534,78.54345477051372,25.55,0.640531606782798,0.5830710071861361,0.5936492469119712,0.5966967232710001,0.7004894895749392,0.3999236226081848,660.299392452324
LLVVGARGV,Positive,=,23700.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.06899845243249825,495.02,971.35,270.6636910435053,256.51336624828014,103.74,0.4265503411717049,0.36424881585642377,0.4823482597770464,0.4873110494902135,0.5709812486997505,0.17828281223773956,7264.812624062459
LLVVGAVGV,Positive,=,25560.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.06201553842241093,50.85,123.99,79.69480273923205,78.90599488547507,25.32,0.6368797937240996,0.5545009527471598,0.5953517476712051,0.5962710980811915,0.7013252478627745,0.3906590044498444,729.9196586591916
LLVVVGARGV,Positive-High,=,6550.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1878557861679665,383.56,613.84,374.8176211436028,484.7077904917272,290.06,0.4501277285082788,0.4066667413028872,0.4522586869835339,0.428496032636525,0.4759515722885126,0.25402486324310297,3201.214619591659
YLVVGAAGV,Positive,=,16410.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.10297180506290493,11.34,14.33,21.79867015818036,20.85018918905801,12.93,0.7755650592398475,0.7539362478733834,0.7151652386023,0.71927677793585,0.7634378334284628,0.5309603214263916,159.95704793007184
YLVVGACGV,Positive,=,26090.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.060118690899308214,12.57,18.46,23.19690265540236,23.556458565952703,13.57,0.7660476068858632,0.730529946877408,0.7094192985398853,0.7079977104059245,0.7589727436832672,0.6407619714736938,48.75831855844395
YLVVGADGV,Positive,=,13420.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.12156227598302373,22.45,28.45,41.82442702068293,40.37476429813407,16.47,0.7124441432712926,0.6905529787614473,0.6549392742443962,0.6581995631983292,0.7410722779572888,0.4314653277397156,469.38301621323
YLVVGARGV,Positive,=,15600.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.10765027346733093,77.56,102.59,72.68252393851051,68.09418087637532,25.37,0.5978612762662909,0.572011519979865,0.6038642514673754,0.6098911041550636,0.7011429172933896,0.3248271048069,1488.0488283897814
YLVVGASGV,Positive,=,21170.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.07943211937343453,22.67,20.62,33.99617060348937,32.144746116854755,13.43,0.7115428447349608,0.7203028196105263,0.6740924077857792,0.6792680100938503,0.759931216494727,0.4675009846687317,317.8314727992588
YLVVGAVGV,Positive,=,22950.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.07197051995451631,11.1,16.96,21.400799588364688,20.946429289619573,13.21,0.7775421043713674,0.7383626950616347,0.7168677393615341,0.7188511527460415,0.7614577627479632,0.5293525457382202,162.7639684791544
YLVVVGAAGV,Positive,=,27740.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.05445098550589855,58.75,65.58,37.30954906051542,49.258365851146,37.16,0.6235328445784065,0.6133681613934748,0.665496907077596,0.6398189393764491,0.6658681149543833,0.4392848610877991,431.30413191197476
YLVVVGADGV,Positive-High,=,5683.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.2009785862475908,82.77,140.49,87.86582679744987,134.42498602520786,68.36,0.5918524797074438,0.5429540068312879,0.5863306217732138,0.5470326479981943,0.6095310137422417,0.4313254356384277,470.0940130070532
YLVVVGASGV,Positive,=,10650.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.14292927938282607,84.01,108.99,62.20424167268146,86.59244451474603,41.2,0.5904781296894885,0.5664184596406533,0.6182525110088517,0.5876798536249068,0.6563295329523335,0.4515303373336792,377.7830714285682
YLVVVGAVGV,Positive,=,15470.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.10842369501540217,59.19,79.21,38.53186233606172,61.02109547446375,39.06,0.6228432319558339,0.5959156982194591,0.6625175307489366,0.6200273680503534,0.6612593318359024,0.4109602868556976,585.9761545963554
YVVVGAVGV,Positive,=,28260.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.05273450279419134,110.47,196.35,178.82572728599598,179.93265987039874,32.65,0.5651718669999891,0.5120141427822436,0.5206545268598122,0.5200841891054686,0.6778265908881855,0.3364800214767456,1311.77840275329
EAAGIGILTV,Positive,,22500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.07380074482379229,6687.84,5322.6,1844.250882727236,2220.6494164111296,3740.17,0.18593098679993325,0.2070339188819874,0.30499237130979073,0.2878269074048133,0.23964372211076224,0.1737959384918213,7626.198452304398
SLLMWITQC,Positive,,4450.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.22358303891823672,422.15,666.69,308.62421621287814,270.46433212139846,332.12,0.44126759881706734,0.39903341830669614,0.4702179418675041,0.4824163598074157,0.4634366623058533,0.3738405108451843,875.5977914646495
EAAGIGILTVI,Positive,,30700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),11,0.04508043862024291,26676.51,15887.41,2993.5050835619318,1794.36173794707,20103.01,0.05806399965121721,0.10596298774545064,0.26022511384573155,0.30752696931509993,0.0842118411653382,0.11654116958379745,14169.23959901537
ELAGIGILTV,Positive,,2480.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2776179295262677,215.85,253.92,124.11377924071788,145.70686026964728,83.55,0.5032630447016206,0.4882502107500545,0.5544087325375758,0.5395842071765453,0.5909855878084099,0.35687461495399475,1052.0270177858058
EMAGIGILTV,Positive,,3600.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.24317403654722725,190.98,233.52,147.17024064056125,172.3772706532325,74.01,0.5145770483957455,0.4959908065396109,0.5386606005146611,0.5240488877485349,0.6021914584505768,0.3860993683338165,766.8327523500342
EIAGIGILTV,Positive,,3350.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2498260674607251,1338.13,1929.12,729.1552380615277,871.9267466519078,588.36,0.3346417822367573,0.3008341741836986,0.390755847056205,0.3742288209359401,0.4105850565681227,0.2597578167915344,3008.6787235150496
EVAGIGILTV,Positive,,4210.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2287071225201845,2083.09,3152.47,1085.9754311778765,1313.6509977029812,822.93,0.2937371315407521,0.2554430100342917,0.3539392681377691,0.33634817904298303,0.3795740572564252,0.20831753313541407,5249.188452337926
ELAGIGILTL,Positive,,4170.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2295894522345869,869.61,819.39,396.1138247863702,479.15938629492524,236.9,0.3744747205187503,0.3799724925368749,0.4471511847058319,0.4295600956110461,0.4946626476586118,0.22478048503398892,4392.71723039312
ELAGIGILTA,Positive,,5610.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.202173485296401,1541.67,1597.3,801.3458644824315,978.3179005429128,459.66,0.3215552730858633,0.31827900822850064,0.3820305306651304,0.3635881911907275,0.43339993439699975,0.21975362300872806,4638.251796640291
ELAGIGILTI,Positive,,2930.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2622069055229073,1040.47,905.68,463.2548768622114,561.6684119737977,256.87,0.3578955473481291,0.3707185245579224,0.4326799282523428,0.4148760265626525,0.4871826414099871,0.2253934442996979,4363.680756166095
ELAGIGILTM,Positive,,36800.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.028330077770162613,2573.38,2143.78,792.1729342246471,949.4672736115787,1146.3,0.2742018105660914,0.2910828943660291,0.3830945936396517,0.3663547549244828,0.34894279180648624,0.1758984625339508,7454.6696913674205
EMAGIGILTL,Positive,,4380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2250484452669637,740.33,875.43,469.69939414863984,566.8654658026629,275.64,0.3893501457178953,0.3738582236958643,0.4314030526829172,0.4140247761830357,0.4806644351866894,0.24484992027282715,3535.3105837974126
EMAGIGILTA,Positive,,3620.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2426619945968299,1220.25,1796.83,950.2108825762633,1157.3907310520633,465.18,0.3431648183579573,0.3073999223263845,0.3662823986422156,0.34805287176271704,0.4322966454581368,0.25020840764045715,3336.1702249656746
EMAGIGILTI,Positive,,1790.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.30775190563500243,878.6,980.84,549.3131554192362,664.4770719031636,281.72,0.3735241560995515,0.3633502308166713,0.4169317962294281,0.3993407071346421,0.4786479425364066,0.2369712144136429,3849.8993522493433
EMAGIGILTM,Positive,,37500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.026588536741671498,2293.04,2397.96,939.3339085474654,1123.2592404835714,1461.42,0.2848620809309431,0.28072706756898524,0.3673464616167369,0.35081943549647243,0.3264960100642491,0.19009709358215326,6393.070058546586
SLLMWITQA,Positive,,1090.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3535973851423163,17.12,25.68,37.53444512185601,38.38044448454869,20.57,0.7374948639376486,0.7000204261580519,0.6649414662048962,0.6628814402862229,0.7205272026671963,0.7367013692855835,17.26761543254955
SLLMWITQL,Positive,,1970.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2988960935861278,11.66,15.61,20.390599754832827,20.659033505576502,19.57,0.7729931135038766,0.7460288314330175,0.7213368038545234,0.7201280283154671,0.7251332048371933,0.7431904673576355,16.096827526226143
SLLMWITQV,Positive,,1190.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3454848703961633,4.55,6.13,7.5758261513405625,7.7109875158635095,12.33,0.8599668872008278,0.8324184930332013,0.8128462196633525,0.8112118189344876,0.7678293167249344,0.8198769688606262,7.020898918048529
SLLMWITQM,Positive,,2380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2814218958748952,47.27,52.12,66.90059803314166,69.04146529296976,46.18,0.6436270925846144,0.6345998366756619,0.6115255048839285,0.6086142285856382,0.6457832403600647,0.5737243890762329,100.70622330347756
SLLMWITQI,Positive,,1360.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.33314345367629183,11.65,15.96,24.85592901698114,25.76973781504873,17.9,0.7730724128100253,0.7439794495592437,0.7030349206927575,0.6996980192046587,0.7333770954435097,0.7077786922454834,23.61234715812017
SALMWITQA,Positive,,2280.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2853891716904157,2076.59,2252.32,960.3510156161524,988.803511407055,709.77,0.2940259769186037,0.2865180900977762,0.3653013325797071,0.3626028688763211,0.3932462568709539,0.5128068923950195,194.67303467151055
SALMWITQL,Positive,,1990.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2979625166013703,1299.6,1070.67,521.71100758257,532.2430510364176,373.33,0.3373420771361281,0.35525112286541216,0.4216966702293342,0.4198494569055653,0.4526262376796442,0.4819909334182739,271.71215430845336
SALMWITQV,Positive,,1700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.31251978233584243,174.77,251.76,193.83401872470662,198.65980278501863,53.46,0.5227748029533955,0.4890397836782038,0.5132060860381635,0.5109332475245858,0.6322536741400853,0.6053597331047058,71.51592769864845
SALMWITQM,Positive,,11400.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1366395513074301,4685.6,3117.47,1711.7092595314382,1778.7298774473675,2841.21,0.2188149301585942,0.2564748700993433,0.3118853712587395,0.3083356571757364,0.2650509938623514,0.32119372487068176,1547.7126262607142
SALMWITQI,Positive,,2030.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2961231855361516,1184.1,1147.56,635.9602918877642,663.9112074331928,296.91,0.34594424346629593,0.3488412569136623,0.4033947870675686,0.399419447794757,0.4737942947703368,0.4611120522022247,340.5793422433625
SMLMWITQA,Positive,,950.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3663029126508308,12.96,19.02,37.70769624875445,38.20410236027925,18.91,0.7632236425199761,0.7277678913844967,0.6645158410150876,0.6633070654760315,0.7283039628542083,0.7643184661865234,12.807384793986225
SMLMWITQL,Positive,,1340.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3345127133224426,8.82,11.53,20.48471848695184,20.564113868697525,18.56,0.7987923769976442,0.774029349769229,0.7209111786647149,0.7205536535052757,0.7300306299652368,0.7595081329345703,13.491619040576884
SMLMWITQV,Positive,,1010.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3606425725190039,3.75,4.88,7.6107945760407345,7.67555874642052,11.71,0.8778389163586858,0.8534955912960788,0.8124205944735439,0.8116374441242962,0.7725976343568182,0.846871018409729,5.242621343944101
SMLMWITQM,Positive,,1570.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.31987230191718885,34.5,36.06,67.20939716316188,68.72424857450943,40.65,0.6727327278841455,0.6686453156862838,0.6110998796941199,0.6090398537754467,0.6575716490113128,0.6080232858657837,69.48432166609791
SMLMWITQI,Positive,,710.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3932163120666763,9.17,11.86,24.97065877249821,25.651336624827966,16.95,0.7951956844197802,0.7714212501809712,0.7026092955029489,0.7001236443944674,0.7384172060249644,0.7338933944702148,17.800285061295046
SILMWITQA,Positive,,1920.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3012721456672733,166.01,206.55,202.03657612610988,211.88977509486907,72.16,0.5275274693131469,0.5073334800655476,0.5093754593298868,0.5049744948672666,0.6045310945123878,0.5729043483734131,101.60373099231171
SILMWITQL,Positive,,5420.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.20535792246113427,82.74,95.07,109.75643695410538,114.05386315774041,54.03,0.591885984632823,0.5790474312275447,0.565770796979514,0.5622210828965108,0.6312734565361365,0.5825462937355042,91.53821595420172
SILMWITQV,Positive,,1060.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3561768084339461,13.55,22.19,40.77838294863293,42.57062242083815,19.29,0.7591090613121776,0.7135207713626968,0.657280212788343,0.6533048735155313,0.7264651133210401,0.6904805302619934,28.47231003516313
SILMWITQM,Positive,,3100.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2569942581858182,622.51,408.29,360.10570353508774,381.1623536313401,320.65,0.4053704684746666,0.4443529665582212,0.4559594980089192,0.4507072831666821,0.4666849879993288,0.41229861974716187,577.5520867167078
SILMWITQI,Positive,,2700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.26976257328889863,73.17,99.52,133.7919550621074,142.26890863868596,48.02,0.603246444792569,0.5748195103388289,0.5474689138177482,0.5417910737857026,0.6421721879115081,0.568202793598175,106.90600998693041
GILGFVFTL,Positive,,1020.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3597319904179632,7.27,15.71,45.75409820495877,48.653042063291714,19.96,0.8166546264257808,0.7454386420989727,0.6466395830431302,0.6409617430110846,0.7233094623392751,0.5655769109725952,109.98692607940495
GILGFVFTL,Positive-High,,7048.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.18108311143651634,7.27,15.71,45.75409820495877,48.653042063291714,19.96,0.8166546264257808,0.7454386420989727,0.6466395830431302,0.6409617430110846,0.7233094623392751,0.5655769109725952,109.98692607940495
LLAAPSAMA,Positive-Intermediate,,37120.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.02752987073120794,244.5,385.15,354.3480115264533,320.70815252345716,91.08,0.4917441777121726,0.4497453910513778,0.4574491861732488,0.4666682277845011,0.5830101021851536,0.254792720079422,3174.728972430431
AAVTSQFPV,Positive-Intermediate,,27710.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.054550992731865366,722.7,384.47,384.0873466234181,389.143696525184,407.68,0.3915777176530441,0.4499087129104614,0.4500007453516001,0.4487919698125439,0.4444911536122723,0.29920488595962524,1963.429084955825
LMAVEEREV,Positive-Intermediate,,34110.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.03534567889885698,518.17,822.74,330.69680573592444,291.816604622462,175.95,0.4223261133962037,0.3795953986357429,0.4638335640203763,0.4753935441755756,0.522152882631884,0.41123682260513306,584.2255017533915
GLMKGGANL,Positive-Intermediate,,16990.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.099761570096086,51.79,64.73,154.67851715411774,142.92559208409853,61.11,0.6351868793722757,0.6145739161248709,0.5340617203387801,0.5413654485958939,0.6198928101112212,0.5724554061889648,102.0984671395925
MLREQLDQV,Positive-Intermediate,,13870.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.11851396002716652,25.47,113.02,98.27204644097138,96.85231369601692,20.17,0.7007793317118032,0.5630626922352535,0.5759858015349182,0.5773307771347127,0.7223421522144564,0.5750378966331482,99.28512266341541
TLHGFVNHI,Positive-Intermediate,,10650.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.14292927938282607,82.98,139.19,306.4996620523416,313.4079437098964,21.92,0.5916182847044771,0.5438132116486036,0.4708563796522168,0.4687963537335434,0.7146522432415916,0.3697355687618256,915.3636395031081
RILSCLSDL,Positive-Intermediate,,29320.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.04933124453934112,375.69,478.47,476.9029402520128,475.45563616977347,128.4,0.4520438238751591,0.4296931646100647,0.42999636143060027,0.4302772740558735,0.5512708057750664,0.4845255315303802,264.3620222330634
GLLHKVKEL,Positive-Intermediate,,30140.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.046781902449804624,334.62,254.9,300.90541275620734,280.61443004119224,91.12,0.4627435602811572,0.4878941910144634,0.4725588804114506,0.4790113582889474,0.5829695211370168,0.4810528755187988,274.4839606840311
ALLVVSREL,Positive-High,,5522.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.2036347542439748,237.39,286.87,185.1100508008356,164.85798981541168,135.24,0.4944716782070983,0.4769736493008501,0.5174623379362482,0.5281710677118303,0.5464739804409829,0.4055523872375488,621.2859057935718
WLAKTRVFL,Positive-High,,5871.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.19797060272782152,44.27,188.5,233.57695902997207,217.8261422038786,42.07,0.6496871611310808,0.5157850864248449,0.4959682658509186,0.5024207437284155,0.6543981956644838,0.4089407920837401,598.9209279335709
ILCKDLSTV,Positive-High,,9327.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.15518890882475578,36.13,55.48,61.154722524373426,63.54918716212552,25.3,0.668466076580509,0.6288257956973913,0.6198251960851944,0.6162754820021912,0.7013982809251655,0.5810544490814209,93.02776287854778
FLTDVACRV,Positive-High,,5380.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.20604254289263926,4.65,5.24,9.25614181717605,10.259117407454506,12.27,0.8579576051189823,0.8469172422211768,0.7943315239066824,0.7848230571663601,0.7682801631586789,0.7952480316162109,9.164807719561047
AVLERYLEL,Positive-High,,5962.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1965490377225576,298.0,145.66,339.17981580823863,341.27934139545687,87.72,0.4734556164876241,0.5396139359004188,0.4614926254764296,0.460922287722086,0.5864841398833207,0.5263895988464355,168.06646626181885
MQSLHFAFL,Positive-Intermediate,,47660.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.004429899809186511,174.89,224.13,250.85918096505455,237.1974413605307,40.96,0.5227113653241957,0.4997839975654542,0.4893710754088869,0.4945466777169584,0.6568694955532905,0.4628994166851044,334.0561951894437
ALEAVRIEL,Positive-High,,5843.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.19841244297482874,651.19,710.01,584.0230661097478,587.6381732407567,179.63,0.4012075582324944,0.3932150103387216,0.4112688530790257,0.4106985153246824,0.5202397828003491,0.4378558397293091,438.02464591462916
TLHDIWPEI,Positive-High,,9314.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.15531781859978788,36.67,15.05,83.83589402353462,90.17995203964212,20.78,0.66709493601425,0.7494054018554536,0.5906698705833116,0.5839279675767446,0.7195884327830804,0.5130451917648315,194.17174668849592
GLYDVQLTI,Positive-Intermediate,,31720.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.04205960572382483,13.11,9.52,40.03409357950166,42.375028177728744,19.0,0.7621600711094546,0.7917337315451201,0.6589827135475771,0.6537304987053398,0.7278651279380701,0.8655858635902405,4.281618765147994
ALLSNDNAL,Positive-High,,8692.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1617057112487147,156.17,139.41,240.1209207496307,227.04398459660686,150.09,0.5331748003766928,0.5436672451154481,0.4934145147120677,0.4985901170201391,0.5368449350400573,0.2865714728832245,2251.0194583362504
LLPMSLHWFI,Positive-Intermediate,,38820.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.023391184277033128,16.25,7.89,158.42364453109616,125.16416314772414,188.64,0.7423151532787895,0.8090907151180718,0.5318505974777248,0.5536298384402261,0.5157164685769112,0.611203670501709,67.13396380876823
LLFAKFSFLI,Positive-Intermediate,,19150.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.08870055047101177,16.6,20.79,48.95758650966036,45.02772447771864,67.63,0.7403456317205284,0.7195439664191501,0.6403850208788942,0.6481186305777147,0.6105232879255317,0.6396546959877014,49.34597958778966
RQLLFSLLAV,Positive-Intermediate,,24610.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.06551614297370212,14.0,50.7,48.95758650966033,46.182772345289784,188.95,0.7560895186347992,0.6371528318418667,0.6403850208788942,0.6457776920337679,0.5155647101061482,0.8345134854316711,5.992612116905082
SLNVDTAFPL,Positive-Intermediate,,45060.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.009614621269452228,23.77,33.75,106.61541457291271,124.30253910918108,291.43,0.7071636591724493,0.6747640917569564,0.5684543638012562,0.5542682762249387,0.4755160696861714,0.5600278973579407,116.79270390928127
TLAGHVYEYI,Positive-Intermediate,,48080.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.003618994231851636,26.57,25.25,118.25513276303428,121.19368757341174,59.64,0.6968715371462455,0.7015811164657935,0.5588777970305652,0.5566092147688856,0.6221432285921036,0.5372610092163086,149.41583890274524
KLIASILYQA,Positive-Intermediate,,16220.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.10404815395921384,22.74,26.27,59.8163625599953,66.4477071903163,46.54,0.7112579013912146,0.6979210185474156,0.6218703251222241,0.6121533020388958,0.6450655404457342,0.6449475884437561,46.59943293980041
FLIHSSTGLI,Positive-Intermediate,,39570.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.02162260111816749,33.25,74.09,115.82971826456809,110.02211770714365,52.14,0.6761435701366734,0.6020916087872294,0.5607931103847036,0.5655473437548646,0.6345643778854144,0.5077397227287292,205.6441110129884
YLQPRTFLL,Positive,,75.0,nM,HLA-A*02:01,I,Literature,2023,Coarse-grained molecular dynamics-guided immunoinformatics to explain the binder and non-binder classification of Cytotoxic T-cell epitope for SARS-CoV-2 peptide-based vaccine discovery.,binding assay,dissociation constant KD,Homo sapiens (human),9,0.6009633469331641,4.3,5.36,12.230099772446508,11.998031560419411,12.3,0.8651899341781183,0.8448245489926672,0.7685811999232677,0.7703518007128709,0.7680544650351719,0.7971401214599609,8.979093301874903
GLYPQLSAI,Positive,,5.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8359529831152714,17.77,27.87,103.37844611848705,102.11981044625587,18.81,0.7340507756695317,0.6924566516960546,0.5713039244470246,0.5724360874519149,0.7287940135020176,0.5638316869735718,112.08353501439026
QLSAIALGV,Positive,,3.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8742140072226278,28.45,54.99,91.29142790373938,86.12118560562679,23.16,0.6905529787614473,0.6296457057448727,0.5827958045718542,0.5881842194748298,0.709566446732779,0.3488326668739319,1147.6666618514869
VVGAAGVGK,Positive,=,11230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.13802817372234089,59.83,147.74,102.33636812979307,117.57094257962468,48.52,0.6218492560705053,0.5383034808302579,0.5722402998646032,0.5594140847697237,0.641214821410046,0.3683539927005768,929.1495944197012
VVGACGVGK,Positive,=,29080.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.05009089267048394,72.99,134.97,104.23894326174305,119.2065173132749,51.66,0.6034740885915133,0.5466586835158486,0.5705377991053692,0.5581372092002981,0.6354191662733601,0.3437148630619049,1213.0094178655766
VVGASGVGK,Positive,=,12710.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.12658613552185505,50.69,114.36,80.17334432591531,91.68536114619249,52.78,0.6371710630946423,0.5619733378194245,0.5947984349244542,0.5823978450193829,0.6334368203468832,0.2822090983390808,2359.8147768124522
VVGAVGVGK,Positive-High,=,5071.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2115094143761372,38.76,65.47,68.0816386199307,82.66087535038571,42.77,0.6619719285475261,0.6135233169723948,0.6099081291626562,0.5919744117900745,0.6528730235026693,0.3995939493179321,662.6588806772533
VVVGAAGVGK,Positive-High,=,7030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1813194548017949,104.17,243.11,61.49361153274806,84.30435305540806,37.47,0.5705989477907696,0.4922711102383082,0.6193144458574241,0.5901548641036434,0.6651002897141998,0.3836603462696075,787.338603101978
VVVGACGVGK,Positive,=,15630.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1074727069657454,122.12,278.8,89.50143530311811,102.52977397953615,40.12,0.5559054870107658,0.4796109004378503,0.5846259928880307,0.5720657935367819,0.6587846011213385,0.3252447843551636,1481.3392104389538
VVVGADGVGK,Positive,=,15030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1110905205326742,194.2,429.98,105.88391726063614,115.57130041198332,46.96,0.5130317445183769,0.4395690432293829,0.5690906734600202,0.5609995386017606,0.6442352075674126,0.3254695534706116,1477.7410416521402
VVVGARGVGK,Positive,=,46140.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.007425545197936367,162.14,308.51,90.95571663684505,103.71701280761008,44.33,0.5297075387495429,0.4702521523948814,0.5831363047237008,0.5710017305622606,0.6495619827792413,0.3531599044799805,1095.1716839910202
VVVGASGVGK,Positive,=,10230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1466479611463769,79.28,213.1,53.19000118548209,73.4260219860633,37.79,0.5958340573094214,0.5044481136152221,0.632721639336392,0.6029236197978984,0.6643143304891337,0.3955666124820709,692.1725267380568
VVVGAVGVGK,Positive-High,=,6954.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1823240661673129,68.99,137.28,46.113703199347285,71.2606861926609,35.83,0.6086831490199263,0.5450902498777108,0.6459160202204559,0.6056901835316537,0.6692367036325164,0.3938203155994415,705.3751477327237
TVLEFILQK,Positive,,2.2,nM,HLA-A*11:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9271281407401551,7.22,9.68,8.433930152776446,9.644950431350725,21.78,0.8172924711633792,0.7901933069590426,0.8029291527408141,0.7905285628357432,0.7152444313998492,0.7945382595062256,9.235460509404538
CWNVEQARF,Positive-High,,1925.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3010317727472659,279.97,368.75,851.0596491020302,572.3082415101952,116.75,0.4792238522400544,0.4537670964875827,0.3764676094343331,0.4131416039141832,0.5600616970675342,0.4634124636650085,332.20696834790834
RVAVILNEF,Positive-High,,2530.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.27577309111665826,967.57,1569.41,907.7369206678109,854.338543482408,470.11,0.3646091820926266,0.3199070407812896,0.3705088567770137,0.3761122124008428,0.4313222925520448,0.2940741777420044,2075.5072945203724
KYISTSLPV,Positive-High,,7135.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.17994922847030093,131.44,240.27,454.9461561308376,453.5550428417685,94.6,0.5491080920984962,0.4933571514212894,0.43435263524829015,0.4346356759995128,0.57950548001402,0.4066813588142395,613.7429238278297
IWEQLASRF,Positive-High,,6405.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1899247855235927,401.23,94.75,434.47020614390055,433.14170326652453,100.92,0.44596509545833785,0.5793590474473762,0.4386088871463753,0.4388919278975977,0.5735284030337822,0.4630234241485596,333.6082814391676
FFNKGGSVF,Positive-Intermediate,,13260.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.12267081503720212,290.57,598.67,1009.1599347312964,1317.1341194590914,77.94,0.4757892110143737,0.4089795224989863,0.3607194774114183,0.3361034445588433,0.5974095600288931,0.2758610248565674,2527.59404309262
LMKGGANLF,Positive-Intermediate,,26720.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.05791344704933155,1258.68,821.12,1018.4975766405183,989.9881586779641,232.21,0.3402989743287008,0.3797775623871785,0.35986822703180144,0.3624922063269708,0.4965107425068169,0.2376239150762558,3822.806845951422
LFTKLHPAF,Positive-Intermediate,,19600.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0865538474610913,234.04,490.66,809.0213821238208,854.3385434824045,41.58,0.4957852279856233,0.42736798659737263,0.3811494865222268,0.3761122124008432,0.6554809918978821,0.4512068629264832,379.1075989912768
SYYMPQLFW,Positive-Intermediate,,27770.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.05435108637639618,41.79,67.36,205.09732685070873,156.9025493305815,71.34,0.6550153821693336,0.6108930091478733,0.5079857930851619,0.5327422822503738,0.6055873727024955,0.5728240013122559,101.69209731888589
EMQSLHFAF,Positive-High,,4845.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2157230673985694,365.9,435.21,628.0005151645744,515.9765923596127,297.74,0.4544841939571351,0.4384516472048877,0.4045588719616948,0.4227181706848744,0.4735362894952912,0.39548608660697937,692.775860154754
KYSDVIKVL,Positive-High,,1376.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3320624666675245,247.58,439.64,837.4521463815693,969.6834870982608,37.29,0.4905871805113359,0.4375156264551491,0.37795729759866303,0.3644075196811093,0.6655453467651198,0.4413831532001496,421.6225271466718
DYPGQGFSF,Positive-High,,5841.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.19844408396645807,305.51,100.14,54.32002985919668,55.033863205636905,59.94,0.4711552897951069,0.5742455080120088,0.6307786603449161,0.6295720129318088,0.6216794878517587,0.5080906152725221,204.86484699651055
RFTLSVPGF,Positive-High,,1597.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3182963685270169,294.69,636.33,610.8857576568441,596.5268551115098,50.46,0.4744879417217383,0.4033410734487065,0.40711262310054575,0.4093109772059065,0.6375913775550504,0.3573300838470459,1046.8553061864814
VYSFLCKTI,Positive-High,,606.9,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.40771762004815537,30.2,55.0,188.78174666745525,152.27548801155638,44.08,0.6850358819929772,0.6296288999741841,0.5156470465017149,0.5355088459841291,0.6500846814671111,0.667780339717865,36.39906421651776
QYDPVAALF,Positive-High,,707.4,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.39355538493559705,66.55,104.98,138.02571323684202,127.53518015983991,31.89,0.6120111304970308,0.5698830665939287,0.5445895594086934,0.5518954157917564,0.6800033799203979,0.5293537378311157,162.76186913359624
HYSPLILAL,Positive,,64.0,nM,HLA-A*24:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.6156221528723917,190.48,314.8,601.1183698856396,637.7199450443057,35.02,0.5148193369412721,0.4683867482912336,0.40860231126487545,0.4031394119536833,0.6713500745222049,0.596924364566803,78.35023806158341
